Policy Trend: Regulatory Upgrading Aligned with International Standards

Taiwan's Food and Drug Administration (TFDA) released new guidance documents in August and September 2026 for C-Reactive Protein (CRP) Assays and Antimicrobial Susceptibility Testing (AST) Systems. These new requirements apply to Class II medical devices and send a clear regulatory signal:

Taiwan is accelerating its alignment with leading international clinical standards such as CLSI, ISO, and IFCC, while significantly raising market entry requirements for high-clinical-value diagnostic devices.

Key Regulatory Changes: Accuracy and Clinical Evidence Become the Core Review Criteria

Compared with previous review practices, both updated guidelines substantially strengthen requirements for performance validation and clinical evidence.

CRP / hsCRP Products

(Enhanced Requirements for Cardiovascular Risk Assessment Claims)

TFDA now clearly distinguishes between conventional CRP and high-sensitivity CRP (hsCRP) products.

If an hsCRP product intends to claim use for cardiovascular disease risk assessment, manufacturers must now:

• Provide additional clinical performance validation data.
• Demonstrate calibration traceability to recognized reference materials, at minimum IFCC/BCR/CAP CRM470.
• Include specific warnings in the Instructions for Use (IFU) indicating that CRP is a non-specific biomarker and should not replace traditional cardiovascular risk factors.

AST Systems

(Mandatory Multi-Center Clinical Validation)

For AST systems used to determine Minimum Inhibitory Concentrations (MICs), the new requirements mandate:

• Accuracy studies conducted at a minimum of three representative testing sites.
• At each site, at least 100 fresh clinical isolates per antimicrobial agent must be tested.
• Major Errors (MD) and Very Major Errors (VMD) must each remain below 3%.
• Quality Control (QC) procedures must fully align with international standards established by organizations such as CLSI or EUCAST.

Commercial and Market Impact: Higher Costs but New Opportunities for Premium Products

These regulatory changes will have tangible business implications for manufacturers entering the Taiwan market.

Reassessment of Registration Timelines and Costs

Due to the requirement for:

• Multi-center clinical isolate studies for AST systems,
• More rigorous Limit of Quantitation (LoQ) validation,
• Precision studies around cardiovascular decision points (e.g., 1.0 mg/L) for hsCRP products,

companies should anticipate longer preparation timelines for TFDA submissions and allocate additional resources for laboratory validation and data generation.

Market Competition Reshaping

Strengthened regulatory oversight is expected to eliminate lower-tier products lacking robust clinical evidence.

Conversely, manufacturers whose products already comply with major international standards, such as:

• Existing CLSI clinical validation data,
• CRM470-traceable calibration systems,

may gain a competitive advantage and leverage their strengths in accuracy, regulatory compliance, and clinical credibility to expand market share in Taiwan.

Recommended Actions: Conduct a Regulatory Gap Analysis Now

As TFDA review requirements become increasingly stringent, IVD manufacturers and distributors should immediately conduct a technical documentation gap analysis for CRP and AST product lines that are either:

• Planned for initial registration, or
• Approaching license renewal.

Key areas requiring review include:

• Performance specifications,
• Interference studies,
• Validation and verification data,
• Clinical performance evidence,
• Compliance with newly introduced standards and criteria.

Ensuring that existing technical documentation can withstand the enhanced TFDA review process will be critical for successful market access and business continuity in Taiwan.

Navigating Taiwan's Evolving IVD Regulations?

With 26+ years of experience and a strong on-site regulatory team at our Taipei office, Qualtech supports IVD manufacturers in assessing regulatory gaps, preparing technical documentation, and navigating TFDA registration requirements.

Contact us to discuss your Taiwan market access strategy.